UPDATE: Bank of America Raises PO on Aegerion Pharmaceuticals on Positive Updates
June 07, 2013 at 11:24 AM EDT
Bank of America analyst Steve Byrne raised the price objective on Aegerion Pharmaceuticals (NASDAQ: AEGR ) from $58 to $100 and maintained a Buy rating. Byrne noted a strong global outlook and less risk to the drug PCSK9 as reasons for the increase. In the report, Bank of America noted,
